BlackRock Inc. - ADAPTIMMUNE THERAPEUTICS PLC ownership

ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 44 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
BlackRock Inc. ownership history of ADAPTIMMUNE THERAPEUTICS PLC
ValueSharesWeighting
Q3 2023$987,577
-8.1%
1,266,124
+8.9%
0.00%
Q2 2023$1,074,968
+11.6%
1,162,128
+31.5%
0.00%
Q1 2023$963,524
-32.2%
883,967
-9.1%
0.00%
Q4 2022$1,420,564
-6.5%
972,989
-31.2%
0.00%
Q3 2022$1,520,000
-34.6%
1,414,247
+3.5%
0.00%
Q2 2022$2,324,000
-15.2%
1,366,907
+2.7%
0.00%
Q1 2022$2,742,000
-37.5%
1,330,839
+13.7%
0.00%
Q4 2021$4,390,000
-32.7%
1,170,693
-7.2%
0.00%
Q3 2021$6,519,000
+55.9%
1,260,872
+28.5%
0.00%
Q2 2021$4,181,000
-47.3%
981,394
-34.3%
0.00%
Q1 2021$7,935,000
+1.2%
1,494,346
+2.7%
0.00%
Q4 2020$7,842,000
+525.9%
1,454,874
+75.4%
0.00%
Q3 2019$1,253,000
-62.0%
829,567
+1.2%
0.00%
Q2 2019$3,297,000
-7.0%
820,121
-0.5%
0.00%
Q1 2019$3,544,000
-28.0%
824,198
-3.8%
0.00%
Q4 2018$4,924,000
-53.2%
856,415
+10.4%
0.00%
Q3 2018$10,514,000
+16.0%
775,405
+1.6%
0.00%
Q2 2018$9,060,000
-0.0%
763,292
-5.4%
0.00%
Q1 2018$9,062,000
+72.3%
806,952
+2.5%
0.00%
Q4 2017$5,258,000
+34953.3%
787,187
+43632.6%
0.00%
Q3 2017$15,000
+114.3%
1,800
+200.0%
0.00%
Q4 2015$7,000
+250.0%
600
+252.9%
0.00%
Q3 2015$2,000
-33.3%
1700.0%0.00%
Q2 2015$3,0001700.00%
Other shareholders
ADAPTIMMUNE THERAPEUTICS PLC shareholders Q4 2019
NameSharesValueWeighting ↓
Syncona Portfolio Ltd 1,377,294$1,501,2502.44%
NEA Management Company, LLC 17,079,779$18,616,9581.29%
Endurant Capital Management LP 1,660,835$1,810,3100.93%
Matrix Capital Management Company, LP 38,974,185$42,481,8620.58%
Long Focus Capital Management, LLC 5,435,439$5,924,6290.34%
PFM Health Sciences, LP 5,992,571$6,531,9020.29%
Key Client Fiduciary Advisors, LLC 321,155$350,0590.22%
DAFNA Capital Management LLC 351,064$382,6600.12%
Rock Springs Capital Management LP 2,787,845$3,038,7510.07%
Baker Brothers Advisors 9,830,877$10,715,6560.06%
View complete list of ADAPTIMMUNE THERAPEUTICS PLC shareholders